Psych MEQs / SAQs · Psychopharmacology — mood stabilisers
Mood stabiliser choice, lithium monitoring and pregnancy hierarchy (MEQ)
FRANZCP-style MEQ on mood stabiliser selection, lithium monitoring, valproate pregnancy hierarchy, lamotrigine titration, and lithium toxicity prevention.
On this page
Study tools
Target exams
Model answer
Reveal model answerShowHide
(i) Preferred strategy and evidence. For bipolar I maintenance after recurrent mania, lithium is the preferred long-term cornerstone when monitoring is feasible: BALANCE showed lithium monotherapy superior to valproate monotherapy for relapse prevention, with combination also effective; lithium also carries an anti-suicide evidence signal. Shared decision covers benefits, monitoring burden, and future pregnancy planning rather than marketing “strength.” Continue or taper olanzapine based on residual symptoms and metabolic risk once a stabiliser is established.[1][2]
(ii) Lithium practicalities. Baseline: eGFR/creatinine, U&E, TFT, calcium, pregnancy test, weight, ECG if indicated. Educate on hydration and interacting drugs. Levels are 12-hour troughs at steady state after initiation/dose change. ISBD/IGSLI-informed maintenance targets commonly around 0.6–0.8 mmol/L for many adults, individualised. Recheck early, then periodically with renal/thyroid/calcium surveillance.[3][7]
(iii) Valproate hierarchy. Do not recommend valproate as routine maintenance given pregnancy potential. EURAP shows high, dose-dependent major malformation risk; Meador NEAD shows adverse cognitive outcomes after fetal valproate. If any discussion of valproate ever occurs under exceptional frameworks, document highly effective contraception, teratogen counselling, and specialist oversight — her inconsistent contraception is a hard stop for casual use.[4][5]
(iv) Lamotrigine. Best for depression-pole prevention/maintenance rather than rapid antimanic rescue. Slow titration (classic 25 mg then 50 mg fortnightly skeleton toward ~200 mg as tolerated); slower with valproate; stop for concerning rash.[6][8]
(v) Interactions and illness. NSAIDs, ACE inhibitors/ARBs, and thiazides raise lithium. In gastroenteritis/dehydration: hold lithium, rehydrate, urgent level and renal panel when unwell, restart only when eating/drinking and levels safe — prevent chronic accumulation toxicity.[7]
References8ShowHide
- [1]Geddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial Lancet, 2010.PMID 20092882
- [2]Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis BMJ, 2013.PMID 23814104
- [3]Nolen WA, Licht RW, Young AH, et al. What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium Bipolar Disord, 2019.PMID 31112628
- [4]Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry Lancet Neurol, 2011.PMID 21652013
- [5]Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs N Engl J Med, 2009.PMID 19369666
- [6]Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder J Clin Psychiatry, 2004.PMID 15096085
- [7]Gitlin M Lithium side effects and toxicity: prevalence and management strategies Int J Bipolar Disord, 2016.PMID 27900734
- [8]Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group J Clin Psychiatry, 1999.PMID 10084633